About Us



Oxyless was founded in 2010, with the purpose of developing an innovative new bloodline for haemodialysis that significantly reduces the degradation of blood during treatment.

Oxyless was founded in 2010, with the purpose of developing an innovative new bloodline for hemodialysis.



After 5 years, we are proud that we have developed a novel bloodline that evidences an improvement in red cell survival and a highly significant reduction in Erythropoietin Simulating Agent (ESA) use.

We are proud to have developed a novel bloodline that reduces blood-air contact by 99.1%. This may provide an alternative strategy in managing renal anemia.



The Oxyless team are committed to improving dialysis patients’ outcomes and reducing the costs <br>of dialysis treatments.

The Oxyless team are committed to improving dialysis patients’ outcomes and reducing the costs
of dialysis treatments.



Oxyless are building close working relationships with nephrologists worldwide to highlight the strengths of the bloodline, so that more dialysis patients can experience the benefits.

Oxyless are building close working relationships with nephrologists worldwide to highlight the strengths of the bloodline, so that more dialysis patients can experience the benefits.